| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	
 
																	Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of ...
 
																	 
																	Jones Trading analyst Soumit Roy initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Buy rating and announces Pr...
 
																	Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of ...
 
																	
 
																	
